Unveiling the Mysteries of Clopidogrel Metabolism and Efficacy | Zendy

Bonello L | Zendy; Bonello N | Zendy; Grosdidier C | Zendy; CamoinJau L | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Unveiling the Mysteries of Clopidogrel Metabolism and Efficacy

Author(s) -

Bonello L,

Bonello N,

Grosdidier C,

CamoinJau L

Publication year - 2011

Publication title -

clinical pharmacology and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.941

H-Index - 188

eISSN - 1532-6535

pISSN - 0009-9236

DOI - 10.1038/clpt.2011.222

Subject(s) - clopidogrel , pharmacogenomics , clinical pharmacology , pharmacology , medicine , pharmacogenetics , platelet , drug , chemistry , aspirin , biochemistry , genotype , gene

Clopidogrel is an important antiplatelet agent, but a considerable variability in the biological effect of the drug has been observed. Additionally, patients with insufficient platelet reactivity inhibition following a loading dose (LD) of clopidogrel have a poor outcome. The mechanisms of variability are dependent on genetic polymorphisms of enzymes involved in clopidogrel metabolism. Paraoxonase 1 has been identified as the main determinant of the biological and clinical efficacy of clopidogrel. This finding could enable the use of pharmacogenomics to tailor antiplatelet agents. Clinical Pharmacology & Therapeutics (2011); 90 6, 774–776. doi: 10.1038/clpt.2011.222

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research